HER2 Support Group Forums - View Single Post - Vitamin D thread -Please use this for your Vit D info.

R.B. · 02-06-2013, 11:02 AM

A trial looking at a vitamin D analogue and HER2 cancers and showing positive outcomes.

Above it appears that vitamin D is relevant to estrogen positive cancers, and below an analogue shows promise in a estrogen negative HER2 positive cancer . . .

Sadly they do not report / nobody appears to have looked at natural Vitamin D and HER2, probably as usual because there is no money to be made, and if they did find it works effectively it would reduce any interest in analogues . . .

Situation 'Human condition' normal . . . )-:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906695/

Gemini Vitamin D Analog Suppresses ErbB2-Positive Mammary Tumor Growth via Inhibition of ErbB2/AKT/ERK Signaling
Hong Jin Lee,1 Jae-Young So,1 Andrew DeCastro,1 Amanda Smolarek,1 Shiby Paul,1 Hubert Maehr,1 Milan Uskokovic,1 and Nanjoo Suh1,2

Numerous synthetic vitamin D analogs have been studied for their effects on the prevention and treatment of breast cancer. However, the inhibitory effects of naturally occurring 1α,25-dihydroxyvitamin D3 or its synthetic analogs on ErbB2 overexpressing mammary tumorigenesis have not been reported. Gemini vitamin D analogs are novel synthetic vitamin D derivatives with a unique structure of two six-carbon chains at C-20. We have previously shown that Gemini vitamin D analogs significantly inhibited carcinogen-induced estrogen receptor (ER)-positive mammary tumorigenesis and reduced ER-negative MCF10DCIS.com xenograft tumor growth without hypercalcemic toxicity. In the present study, we have determined the inhibitory effect of a potent Gemini vitamin D analog BXL0124 (1α,25-dihydroxy-20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol) on the ErbB2/Her-2/neu overexpressing mammary tumorigenesis. The Gemini BXL0124 inhibits ErbB2-positive mammary tumor growth and down-regulates the phosphorylation of ErbB2, ERK and AKT in tumors of MMTV-ErbB2/neu transgenic mice. These effects of Gemini BXL0124 in vivo were confirmed by using the ErbB2 overexpressing tumor cells derived from the mammary tumors of MMTV-ErbB2/neu mice. In conclusion, the Gemini vitamin D analog BXL0124 inhibits the growth of ErbB2 overexpressing mammary tumors through regulating the ErbB2/AKT/ERK signaling pathways, suggesting that Gemini vitamin D analog may be considered for translational studies.

And from the body of the text

"In conclusion, the Gemini vitamin D analog BXL0124 inhibits ER-negative/ErbB2 positive mammary tumorigenesis without hypercalcemic toxicity via regulating ErbB2/ErbB3-driven downstream signaling, ERK, AKT and cell cycle regulator, cyclin D1. Taken together with our previous study [10], Gemini vitamin D analogs, especially BXL0124, may be potent agents in the prevention of different types of human breast cancer without toxicity, and should be considered for translational studies."

02-06-2013, 11:02 AM	#36
R.B. Senior Member Join Date: Mar 2006 Posts: 1,843	Re: Vitamin D thread -Please use this for your Vit D info. A trial looking at a vitamin D analogue and HER2 cancers and showing positive outcomes. Above it appears that vitamin D is relevant to estrogen positive cancers, and below an analogue shows promise in a estrogen negative HER2 positive cancer . . . Sadly they do not report / nobody appears to have looked at natural Vitamin D and HER2, probably as usual because there is no money to be made, and if they did find it works effectively it would reduce any interest in analogues . . . Situation 'Human condition' normal . . . )-: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906695/ Gemini Vitamin D Analog Suppresses ErbB2-Positive Mammary Tumor Growth via Inhibition of ErbB2/AKT/ERK Signaling Hong Jin Lee,1 Jae-Young So,1 Andrew DeCastro,1 Amanda Smolarek,1 Shiby Paul,1 Hubert Maehr,1 Milan Uskokovic,1 and Nanjoo Suh1,2 Numerous synthetic vitamin D analogs have been studied for their effects on the prevention and treatment of breast cancer. However, the inhibitory effects of naturally occurring 1α,25-dihydroxyvitamin D3 or its synthetic analogs on ErbB2 overexpressing mammary tumorigenesis have not been reported. Gemini vitamin D analogs are novel synthetic vitamin D derivatives with a unique structure of two six-carbon chains at C-20. We have previously shown that Gemini vitamin D analogs significantly inhibited carcinogen-induced estrogen receptor (ER)-positive mammary tumorigenesis and reduced ER-negative MCF10DCIS.com xenograft tumor growth without hypercalcemic toxicity. In the present study, we have determined the inhibitory effect of a potent Gemini vitamin D analog BXL0124 (1α,25-dihydroxy-20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol) on the ErbB2/Her-2/neu overexpressing mammary tumorigenesis. The Gemini BXL0124 inhibits ErbB2-positive mammary tumor growth and down-regulates the phosphorylation of ErbB2, ERK and AKT in tumors of MMTV-ErbB2/neu transgenic mice. These effects of Gemini BXL0124 in vivo were confirmed by using the ErbB2 overexpressing tumor cells derived from the mammary tumors of MMTV-ErbB2/neu mice. In conclusion, the Gemini vitamin D analog BXL0124 inhibits the growth of ErbB2 overexpressing mammary tumors through regulating the ErbB2/AKT/ERK signaling pathways, suggesting that Gemini vitamin D analog may be considered for translational studies. And from the body of the text "In conclusion, the Gemini vitamin D analog BXL0124 inhibits ER-negative/ErbB2 positive mammary tumorigenesis without hypercalcemic toxicity via regulating ErbB2/ErbB3-driven downstream signaling, ERK, AKT and cell cycle regulator, cyclin D1. Taken together with our previous study [10], Gemini vitamin D analogs, especially BXL0124, may be potent agents in the prevention of different types of human breast cancer without toxicity, and should be considered for translational studies." Last edited by R.B.; 02-06-2013 at 11:23 AM..